DAVIS, Calif., Aug. 12, 2022 /PRNewswire/ -- Arcadia Biosciences, Inc.^® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced today that it has entered into securities purchase agreements with a single healthcare-focused institutional investor for the purchase and sale of 4,722,506 shares of its common stock (or common stock equivalents) at a purchase price of $1.05876 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, the company agreed to issue to the investor in the offerings unregistered preferred investment options to purchase up to an aggregate of 4,722,506 shares of common stock. The unregistered investment options will be exercisable immediately upon issuance at an exercise price of $0.93376 per share and will expire five years from the date of issuance.